NASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis $8.94 -0.12 (-1.32%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.69▼$9.1950-Day Range$6.19▼$9.4852-Week Range$5.70▼$12.63Volume830,459 shsAverage Volume1.38 million shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice Target$21.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Relay Therapeutics alerts: Email Address Relay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.6% Upside$21.60 Price TargetShort InterestBearish6.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 7 Articles This WeekInsider TradingSelling Shares$354,836 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.81) to ($2.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.72 out of 5 starsMedical Sector694th out of 936 stocksBiological Products, Except Diagnostic Industry115th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingRelay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRelay Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Relay Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.35% of the outstanding shares of Relay Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 4.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLAY. Previous Next 2.8 News and Social Media Coverage News SentimentRelay Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Relay Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for RLAY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $354,836.00 in company stock.Percentage Held by InsidersOnly 4.32% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.81) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Relay Therapeutics Stock (NASDAQ:RLAY)Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More RLAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLAY Stock News HeadlinesJuly 2, 2024 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $58,487.52 in StockJuly 24 at 8:19 PM | finance.yahoo.comWe're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn RateJuly 27, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.July 23, 2024 | americanbankingnews.comBrokerages Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $21.80July 20, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 3.1% After Analyst DowngradeJuly 19, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Price Target Cut to $21.00 by Analysts at JMP SecuritiesJuly 19, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Analyst DowngradeJuly 18, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) PT Lowered to $18.00July 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.June 24, 2024 | seekingalpha.comRelay Therapeutics: A 'Concept' StockJune 6, 2024 | globenewswire.comRelay Therapeutics Discloses Three New Programs at New Program & Platform EventJune 5, 2024 | globenewswire.comRelay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608May 21, 2024 | globenewswire.comRelay Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2024 | globenewswire.comRelay Therapeutics to Host New Program and Platform Event on June 6, 2024May 10, 2024 | msn.comRelay Therapeutics upgraded by Barclays ahead of data readoutMay 10, 2024 | msn.comBarclays Upgrades Relay Therapeutics (RLAY)May 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst ConfidenceMay 4, 2024 | finance.yahoo.comRelay Therapeutics First Quarter 2024 Earnings: Beats ExpectationsSee More Headlines Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$21.60 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+143.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-341,970,000.00 Net MarginsN/A Pretax Margin-931.61% Return on Equity-42.66% Return on Assets-37.04% Debt Debt-to-Equity RatioN/A Current Ratio20.73 Quick Ratio20.73 Sales & Book Value Annual Sales$25.55 million Price / Sales46.45 Cash FlowN/A Price / Cash FlowN/A Book Value$5.90 per share Price / Book1.52Miscellaneous Outstanding Shares132,740,000Free Float127,008,000Market Cap$1.19 billion OptionableOptionable Beta1.66 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Independent Chairman Comp: $92.5kDr. Sanjiv K. Patel M.A. (Age 50)M.B.A., M.D., MBBS, CEO, President & Director Comp: $1.08MDr. Mark Murcko Ph.D. (Age 64)Co-Founder & Director Comp: $60kMr. Thomas Catinazzo (Age 47)Chief Financial Officer Comp: $663.99kMr. Brian R. Adams J.D. (Age 50)Chief Legal Officer & Secretary Comp: $627.72kMr. Peter RahmerChief Corporate Development OfficerDr. Donald A. Bergstrom M.D. (Age 52)Ph.D., President of Research & Development Comp: $1.37MDr. Deborah Palestrant M.B.A.Ph.D., Vice President of Corporate Development & StrategyMr. Jim Watters Ph.D.Chief Scientific Officer of Late ResearchDr. Beni B. Wolf M.D.Ph.D., Chief Medical Officer & Head of Precision MedicineMore ExecutivesKey CompetitorsVir BiotechnologyNASDAQ:VIRFive Prime TherapeuticsNASDAQ:FPRXAllogene TherapeuticsNASDAQ:ALLOFate TherapeuticsNASDAQ:FATEApellis PharmaceuticalsNASDAQ:APLSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 48,219 shares on 7/26/2024Ownership: 0.267%Allspring Global Investments Holdings LLCBought 29,087 shares on 7/26/2024Ownership: 0.029%Baillie Gifford & Co.Sold 69,168 shares on 7/25/2024Ownership: 0.214%Donald A BergstromSold 648 sharesTotal: $4,056.48 ($6.26/share)Thomas CatinazzoSold 9,373 sharesTotal: $58,487.52 ($6.24/share)View All Insider TransactionsView All Institutional Transactions RLAY Stock Analysis - Frequently Asked Questions How have RLAY shares performed this year? Relay Therapeutics' stock was trading at $11.01 at the beginning of the year. Since then, RLAY stock has decreased by 18.8% and is now trading at $8.94. View the best growth stocks for 2024 here. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its earnings results on Thursday, May, 2nd. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.08. Relay Therapeutics's revenue was up 4327.9% compared to the same quarter last year. When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $250 million in an IPO on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Top institutional shareholders of Relay Therapeutics include Bank of New York Mellon Corp (0.27%), Baillie Gifford & Co. (0.21%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Mark Murcko, Donald A Bergstrom, Peter Rahmer, Thomas Catinazzo, Brian Adams, Andy Porter and Sanjiv Patel. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG) and DraftKings (DKNG). This page (NASDAQ:RLAY) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
